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Abstract
Background: Parenteral Nutrition (PN) is prescribed to children with intestinal failure. Although life saving, complications
are common. Recommendations for indications and constituents of PN are made in the 2005 guidelines by the European
Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). The aim of this study was to establish if the
indications for prescribing PN in a tertiary children’s hospital were appropriate, and to identify complications encountered.
Data were compared to those published by the National Confidential Enquiry into patient outcome and death (NCEPOD)
carried out in the United Kingdom in 2010.
Methods: Children and newborns receiving inpatient PN over a 6 months period were entered into the study and data
was collected prospectively. The appropriate indications for the use of PN were based on the ESPGHAN guidelines.
Recorded complications were divided into metabolic, central venous catheter (CVC) related, hepatobiliary and
nutritional.
Results: A total of 303 children (67 newborns) were entered into the study. The main indications for the start
of PN were critical illness (66/303), surgery (63/303) and bone marrow transplantation (28/303). The ESPGHAN
recommendations were followed in 91.7% (278/303) of cases (95.5% of newborns, 90.7% of children). PN was
considered inappropriate in 12/303 patients and equivocal in 13. The mean PN duration was 18 days (1–160)
and the incidence of complications correlated to the length of PN prescribed. Metabolic, hepatobiliary and CVC
related complications affected 74.6, 24.4, 16.4% of newborns and 76.7, 37.7 and 24.6% of children respectively.
In relation to the appropriate indications for the start of PN our results mirrored those reported by the NCEPOD
audit (92.4% of newborns and 88.6% children). However, the incidence of metabolic disturbances was higher
in our cohort (74.6% vs 30.4% in children, 76.7% vs 14.3% in newborns) but CVC related complications lower
amongst our newborns (16,4% vs 25%).
Conclusions: Although the indications for inpatient PN in children is mostly justified, there is still a proportion
who is receiving PN unnecessarily. PN related complications remain common. There is a need for better education
amongst health professionals prescribing PN and access to nutritional support teams to reduce unwanted side effects.
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Background
Parenteral Nutrition (PN) is used when nutrition cannot
be tolerated via the oral or enteral route [1]. Since its
first use in the late 1960s PN has become a well estab-
lished therapy and a lifesaver in well selected hospita-
lised newborns and children with intestinal failure (IF)
or those who fail to meet their nutritional requirements
with enteral intake alone [2].
However, PN is bay far no panacea, quite invasive and
associated with potentially fatal complications [3]. Central
venous catheter (CVC) related infection, occlusion, central
venous thrombosis, pulmonary embolism and accidental
catheter removal or damage, electrolyte disturbances and
renal abnormalities, metabolic bone disease, micronutrient
deficiencies and liver disease are well known complica-
tions of PN [3, 4].
It is hence crucial to weigh the potential benefits
against the risks to the patient, led alone the cost impli-
cations to the health care system [5].
In 2005 the European Society of Paediatric Gastroenter-
ology, Hepatology and Nutrition (ESPGHAN) and the
European Society for Clinical Nutrition and Metabolism,
supported by the European Society of Paediatric Research,
have published guidelines on the use of PN in children,
aiming at identifying the most common and reasonable
indications for the use of PN in newborns, infants and
children in order to reduce its inappropriate use [6]. The
authors make recommendations when to start PN and
how to minimise the related complications [6].
Much is published on the use and incidence of compli-
cations occuring in adults receiving intravenous nutrition
in hospital [7, 8]; however little is known in children [6].
In 2010 the National confidential enquiry into patient
outcome and death (NCEPOD) conducted a retrospect-
ive survey on a random sample of patients receiving PN
in hospital in the United Kingdom including children
and newborns [9]. The purpose of this enquiry was to
reveal areas of deficiency in the use of PN in hospitalised
patients and to make recommendations how to resolve
them [9]. The neonatal cohort included 264 subjects but
the audit in the paediatric age group consisted of just 70
patients [9]. In the neonatal cohort 92,4% of the indica-
tions for PN were considered appropriate [9]. In the
paediatric age group (1 month to 19 years) 88% of chil-
dren were given PN for justified reasons [9]. Moreover
the audit showed that in children complications associated
with PN still frequently occur: metabolic disturbances af-
fecting 30,4% of children and 14,3% of newborns, and
CVC related complications encountered in 25% of new-
borns, were amongst the most common ones [9]. The
need of a large scale audit of PN care in children was
hence suggested [9].
The aim of this observational study was hence to get a
better understanding why children in hospital are started
on PN and if the indications, based on the 2005 ESP-
GHAN guidelines, are appropriate and to estimate the
incidence of PN related complications. We wanted to
compare our results to the NCEPOD audit and, if
needed, develop strategies to avoid inappropriate PN
prescribing in the future.
Methods
All newborns, infants and children admitted to Great
Ormond Street Hospital who started PN were identified
from the pharmacy database and enrolled prospectively
over a 6 months study period between October 2013
and March 2014. Patients established on home PN were
excluded. Information was obtained from the PN pre-
scription, medical, nursing and dietetic records.
Indications for starting PN
Patient demographics, weight and height/length, refer-
ring department (medical, surgical, intensive care),
underlying diagnosis, current pathology, feeding regime
prior to and on PN, reason for starting PN and duration
were recorded. Under-nutrition in children was defined
according to the World Health Organistation criteria
[10]. The indications for prescribing PN were divided ac-
cording to specialty into medical and surgical, and pri-
mary or secondary IF. Primary IF was defined as
requirement for intravenous nutrition due to an under-
lying anatomical, structural gut pathology; IF was con-
sidered secondary if PN was started as a consequence of
other conditions leading to enteral feed intolerance. The
indications for starting PN were classified as appropriate,
inappropriate or indeterminate based on the ESPGHAN
2005 guidelines [6]. In newborns with a very low or ex-
tremely low birth weight indications for PN were based
on separate guidelines applicabable to this specific group
of patients [11] (Tables 1 and 2).
Table 1 Appropriate indications for PN in infants and children [6]
1 Infants aged 1 to 12 months: inability to achieve an adequate
energy intakea for more than 3 days
2 In children older than 1 year: inability to achieve an adequate
energy intakea for more than 5 days
3 Children not expected to meet an appropriate energy and
nutrient intake for more than 7 days
4 Clinical condition leading to an absolute or relative
contraindication to enteral nutritionb
5 In children older than 1 year: duration of PN of at least 5 days
except in undernourished children
aadeguate energy intake defined as 60–80% of the Kcal for age [5]
babsolute contraindications to enteral nutrition: paralytic or mechanical ileus,
anatomical disruption of the gastrointestinal (GI) tract, intestinal obstruction,
necrotising enterocolitis, GI ischemia, diffuse peritonitis, bowel perforation or a
state of severe shock [5, 16, 90]
Relative contraindications to enteral nutrition: gastro-intestinal bleeding,
intractable diarrhea, enteric fistula, toxic megacolon, gastro-intestinal
dysmotility, severe vomiting [5, 16, 90]
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The use of PN in relation to appropriateness was con-
sidered indeterminate if a judgement could not be made
due to lack of enough clinical information to be able to
reach a conclusion if PN was used appropriately, if EN
was achievable but not used because of concerns over
potential complications associated with feeding or a
delay in passing a suitable enteral feeding tube, eg if the
child did not cooperate with the insertion of a nasal
feeding device or if jejunal feeding was required but je-
junal access was unsuccesful.
PN Complications
Bloods for vitamins (A,D,E), folate, trace elements (zinc,
selenium, copper, iron and mangnesium) and ferritin
were sent when patients were started on PN.
Electrolites, urea, peripheral blood glucose, carbon diox-
ide (CO2) and pH were monitored daily for at least 10
days; subsequent testing was based on the patients clinical
needs. Liver function tests (LFTs) including alanine amino-
transferase (ALT), aspartate aminotransferase (AST), alka-
line phosphatase (ALP), gamma-glutamyl transpeptidase
(GGT) and bilirubin, urinary sodium (uNa) and triglycerids
(TG) were performed at least weekly. In children who
remained on PN for more than 28 days vitamins and trace
elements were checked after one month of nutritional sup-
port and continued to be monitored every four weeks for
the duration of PN.
All children were followed on a daily basis and any
complications recorded.
Complications were divided into metabolic, CVC re-
lated, nutritional and hepatobiliary and defined as follows:
1) metabolic: deficiency or excess of electrolytes, hypo
and hyperglycemia, hypercapnia, acid–base
disturbances, rise in urea, hypertriglyceridemia
and low uNa;
– electrolytes abnormalities were defined as at least
two consecutive results above or below the
reference value for age and divergent from
baseline levels, requiring a change of PN
prescription or oral/iv supplementation; calcium
and magnesium were corrected for the albumin
level, serum sodium was corrected in the
presence of hyperglycemia [12]. Patients were
monitored for hypophospathemia throughout
the duration of PN, which was considered a
marker of refeeding syndrome (RS) in the first
10 days of PN in malnourished children or those
who had lost a significant amount of weight
prior to the start of PN [13].
– Hypoglycaemia was defined as a blood glucose
level of less than 3.6 mmol/l (40 mg/dl) both in
newborns and in children [14, 15]. Children
were considered hyperglycaemic if their blood
sugare rose above 7 mmol/L (126 mg/dl) [14]. In
newborns plasma glucose concentrations above
8 mmol/l (150 mg/dL) were considered
pathological in accordance with the guidelines
of the American Society for Parenteral and
Enteral Nutrition [14].
– Blood triglyceride concentrations were checked
on a weekly basis 4 h after stopping the lipid
infusion; levels > 200 mg/dl in newborns, >
250 mg/dl in infants and > 400 mg/dl in children
were considered pathological [16].
– uNa was considered low if < 20 Meq/L.
– A rise in urea due to renal failure or gastro-
intestinal bleeding was not recorded [17, 18].
– Acid-base disturbances as a consequence of
respiratory failure, sepsis and metabolic disease
were not considered to be related to PN.
– Hypercapnia secondary to respiratory failure was
not recorded.
2) CVC related complication: Exit site and central line
associated bloodstream infections (CLABSIs), line
colonisation, occlusion, thrombosis, damage,
misplacement, phlebitis, extravasation and venous
thrombosis; CLABSIs were defined according to the
2012 guidelines of Centers for Disease Control and
Prevention [19]. All organisms causing CLABSIs
were recorded.
3) Nutritional complications: deficiency or excess of
vitamins and trace elements after 30 days of PN and
divergent from baseline values were recorded;
Vitamin concentrations were measured by high
pressure liquid cromatography (HPLC). Ferritin was
used as a marker of iron storage in the presence of
a normal C-reactive protein [20]. As ferritin syntesis
is enhanced by cytokines, high values were not
considered due to iron overload when inflammation
was present or the inflammatory markers were
elevated [20].
In particular, if data were available, we followed ESP-
GHAN guidelines for reference values:
– we defined a high vitamin E level as greater than
3.5 mg/dl and low Vitamin E levels < 1 mg/dL and <
0.5 mg/dl in premature infants and children
respectively [6, 21, 22].
– 300–800 microG/L were considered normal
reference values for vitamin A in children older than
Table 2 Appropriate indications for PN in newborns [5, 11]
1 < 32 weeks of gestation and/or < 1500 g
2 > 32 weeks of gestation with IF
3 Bridging PN
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6 months of age. Serum concentrations below 200
microg/L were considered to indicate deficiency in
premature infants [6].
We used reference values obtained from the ESP-
GHAN guidelines considered normal for sex and age if
no data was available from our laboratory.
4) Hepatobiliary complications: any prolonged (at least
two weeks) rise in LFTs not explained by other
causes (eg medication, metabolic disorder, haemolysis,
surgical obstruction) 1.5 × above the normal value for
age was recorded. Hyperbilirubinaemia was defined as
> 50 micromol/L.
The study was approved by the Ethical Committee of
Great Ormond Street Hospital and informed consent
was obtained from parents or legal guardians of the pa-
tients. All data collected were analysed using Microsoft
Access and Excel.
Results
Population characteristics
Over a 6 months period PN was prescribed to 318 new-
borns and children; fifteen patients were excluded as
already established on home PN. A total of 303 were
hence included in the study; 236 (77.9%) were older than
1 month of age, 67 (22,1%) were newborns; the median
age was 38 months (range 0-223), 54.5% were females,
89 patients were malnourished (29,4%).
Only 17 patients did not have a pre-existing diagnosis,
90 children suffered from congenital heart disease, 68
had a diagnosis of malignancy (54,4% leukemia, 46,6%
solid tumour) and 41 had a known pathology of the GI
tract. All the underlying diagnoses are listed in Table 3.
Children were referred for PN from medical (34%, ma-
jority oncology 57/103), surgical (35%, majority cardio-
thoracic 81/106) and Intensive Care Units (31%). Main
indications for prescribing PN were critical illness (66/
303), pre, peri and post surgery nutritional support (63/
303) and bone marrow transplantation (28/303).
The majority of children (57.4%) who were prescribed
PN had secondary IF as a consequence of an acute or
chronic medical condition. Multi-organ, respiratory, renal
or heart failure, shock, sepsis and macrophage activation
syndrome were the most common causes (21.8%) followed
by bone marrow transplantation (9.8%) or feed intolerance
due to chemotherapy (8.2%) or radiation induced mucosi-
tis. The indications for PN are listed in Table 4.
At the end of the study all but 15 patients were
weaned off PN. The mean duration of PN was 18 days
(range from 1-160 days), 55 patients (18,2%) had more
than 28 days of intravenous support.
Appropriatness of indications for prescribing PN
PN was considered appropriate in 278/303 (91,7%), in-
appropriate in 12 (4,0%) and indeterminate in 13 (4,3%)
patients.
PN was defined inappropriate in 5 non malnourished
children older than 12 months who had less than 5 days
of PN where it was not anticipated at the start that PN
Table 3 Underlying diagnosis
Pre-existing diagnosis No Percentage
Cardiac disease 90 29,7
Malignancy 68 22,4
GI pathology 41 13,5
Immune dysfunction 20 6,6
No pre existing pathology 17 5,6
Metabolic disorder 16 5,3
Prematurity 16 5,3
Neurological abnormality 15 5,0
Syndrome 7 2,3
Endocrine disorder 3 1,0
Congenital bone diseases 3 1,0
Lung disease 3 1,0
Rheumatological disorder 3 1,0
Table 4 Indications for PN
Indication No Percentage
Critical illness 66 21.8
Pre-peri-post surgery nutritional support 63 20.8
Bone marrow transplantation 28 9.2
Feed intolerance 25 8.2
NEC 22 7.3
Intestinal resection in congenital malformation of the
GI tract
21 6.9
Mucositis due to chemotheraphy 19 6.3
Other intestinal resections 10 3.3
Condition associated with malabsorption 9 3.0
Decompensation in patients with metabolic condition 7 2.3
Organ transplant 6 2.0
Post surgical ileus 4 1.3
Autoimmune disorder associated with intestinal failure 4 1.3
GI dysmotility 4 1.3
Miscellaneus 4 1.3
Post operative nutritional support 3 1.0
Malnourishment 3 1.0
Meconium aspiration 2 0.7
Acute pancreatitis 2 0.7
Heart cachexia 1 0.3
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would be required for longer; moreover four infants
were given PN despite a functional GI tract and one was
kept nil by mouth and given PN for one day for query
NEC but started again on feeds the following day. Finally
two term newborns were precribed PN unnecessarily as
they were able to tolerate >80% of their requirements
enterally when PN was started and PN was only given
for one day.
According to age PN was defined as appropriate in
95,5% of newborns and in 90,7% of infants and children.
Our results were similar to the data reported in the
NCEPOD audit [9] Table 5.
Complications
A total of 239/303 (78,9%) patients developed complica-
tions as a consequence of PN; the mean duration of PN
in these children was 22 days (range 2-160) whereas
those who experienced no complications received PN
for a mean of 5 days (range 1-23). All patients who had
PN for more than 28 days developed complications.
Metabolic complications were the commonest occuring
in 76.2% of patients: hyperphosphatemia was the most fre-
quent (111 patient, 36.6%), followed by hypermagnesemia
(31,4%) and hypercalcemia (29,7%). In particular hyper-
phosphatemia developed in 8/89 malnourished patients.
Hypophosphatemia was seen in 84 patients (27,7%) and
66/84 (59,9%) developed it in the first 10 days of PN ad-
ministration. RS was blamed in 13/66 patients as they
were malnourished or had lost a significant amount of
weight prior to the start of PN. However, most malnour-
ished patients (85.4 %) did not develop hypophosphatemia
in the first days after being started on intravenous
support.
Hyperglycemia and hypoglycemia affected 32 (10.6%),
and 9 (3.0%) of all children respectively. Twenty-seven
(8.9%) children developed hypercapnia. Acid-base distur-
bances were noted in 55 children, 36/303 (11.9%) devel-
oped acidosis.
All metabolic complications are listed in Table 6.
Hepatobiliary complications were found in 106 patients
(35,0%). A rise in ALT was the commonest affecting 82/303
(27.1%). Elevation of GGT occured in 38 children (12,5%);
an abnormal bilirubin in 31 (10,5%). Rise in ALP was docu-
mented in 14 patients. Just 5 had an elevated AST.
Twenty-one patients with a derangement of LFTs had a
concomitant line infection, 45/106 (42,5%, 14.8% of the
total population) had a rise in more than one liver param-
eter. The mean duration of PN in patients who developed
hepatobiliary complications was 31 days versus 12 days in
children who did not experience any alteration in LFTs.
CVC related complications affected 69 (22,8%) chil-
dren, the commonest being blockage of the line (36,
11.6%). Thirty-one children (10.2%) developed a line in-
fection (no child had more then one episode). The
principle organism involved was coagulase negative
staphylococcus grown in 17/31 (54,8%) blood cultures
followed by Streptoccocus species (5/16,1%) and Can-
dida species (3, 9.7%). Line infections with gram negative
organisms occured in 4 children (12.9%) and was caused
by Enterobacteriacae (2/4), Escherichia coli (1/4) and
Pseudomonas Aeruginosa (1/4). The mean duration of
Table 5 Appropriatness of PN divided by age and compared to the NCEPOD audit
Current Audit NCEPOD
Newborns Infants/children Newborns Infants/children
No, Percentage No, Percentage No, Percentage No, Percentage
Appropriate 64, 95.5 214, 90.7 244, 92.4 62, 88.6
Indeterminate 1, 1.5 12, 5,1 4, 1.5 /
Inappropriate 2, 3.0 10, 4.2 16, 6.1 8, 11.4
Table 6 Metabolic complications
Metabolic complication No Percentage among
all patients
Hyperphophatemia 111 36,6
Hypermagnesemia 95 31,4
Hypercalcemia 90 29,7
Hypophosphatemia 84 27,7
Rise in urea 74 24,4
Hypokalemia 70 23,1
Hypophosphatemia in the first 10 days 66 21,8
Hypernatremia 36 11,9
Acidosis 36 11,9
Hyponatremia 35 11,6
Hyperkalemia 32 10,6
Hyperglycemia 32 10,6
Hypercarboxinemia 27 8,9
Hypomagnesemia 25 8,3
Hypertrigliceridemia 21 6,9
Hypocalcemia 19 6,3
Alcalosis 19 6,3
Hypercloremia 14 4,6
Hypocloremia 13 4,3
Low urinary sodium 12 4,0
Hypoglycemia 9 3,0
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PN in children who developed a line infection was 37
days versus 17 days in children who did not develop
CLABSIs. The central venous catheter was subsequently
removed and replaced with a new line in 11/31(15.9%)
patients. Colonisation of the line was found in 9/31 pa-
tients, mostly with Coagulase negative Staphylococcus
(5/9, 55.6%). Four children experienced a catheter break-
age which required repair.
Thirty-five/303 (11,6%) children developed nutritional
complications. Of the 55 children who received PN >28
days, 37 had nutritional bloods performed. 35/37 (94,6%)
showed a deficiency or excess in the levels of fat soluble
vitamins and/or trace elements. The most common ab-
normal results seen were a rise in vitamin A and E levels
and low levels of selenium with 27.3%, 25.5% and 29.1% of
patients affected respectively. All the nutritional complica-
tions encountered are listed in Table 7.
According to age metabolic complications affected
74.6% of all newborns, the commonest being hyperpho-
phatemia (33/67) and hypermagnesemia (30/67), and
76.7% of all children. Hyperglycaemia developed in
10.45% of newborns, and hypoglycemia in 6.0%. Seven-
teen (25.4%) of newborns and 89 (37.7%) of children
showed a derangement in their LFTs.
Eleven newborns (16.4%) and 58 children (24.6%) de-
veloped CVC related complications, in particular 4 new-
borns had a culture positive CLABSIs.
Nutritional complications developed in 3 newborns
and 32 children.
Comparison between our audit and the NCEPOD is
reported in Table 8 [9].
Discussion
Feeding children with a non functioning gut intraven-
ously or those who are unable to meet their nutritional
requirements enterally is a well established practice.
However, PN is by far no panacea and its use may cause
serious complications to the patient and put a huge fi-
nancial burden to the health care system [3, 4, 23], The
2005 ESPGHAN guidelines make recommendations
when PN should be prescribed to children [6]. In 2010
the NCEPOD conducted a national retrospective audit
in the UK on adults and children receiving PN: indica-
tions for PN were considered appropriate in 92.4% of
newborns and in 88.6% of children aged >1month [9].
Complications were demonstrated to be common. Meta-
bolic disturbances occured in 30,4% of children and
14,3% of newborns of which 25% also developed CVC
related complications [9].
The NCEPOD audit revealed suboptimal care in the
administration of PN in newborns and children and
pointed out the importance of the Nutrition Support
Team (NST) [9]. However, as only 70 children were in-
cluded in the data analysis, a larger scale audit of PN
care in children was recommended [9].
The findings of our study mirror those of the NCEPOD;
yet our data was collected prospectively and based on a
much bigger cohort of 236 children. Although our neo-
natal group was smaller (67 versus 264 NCEPOD) we had
similar results in this age group as well. In our cohort the
use of PN was appropriate in 95.5% of newborns and
90.5% of children (aged 1 month-18 years). We observed a
high complication rate with 78.9% of patients being af-
fected. Similar to the NCEPOD audit, metabolic distur-
bances were the most frequently occuring problem and
exceeded the percentage of children affected in the 2010
retrospective NCEPOD study. However, CVC related
complications were less common in our population com-
pared to the NCEPOD audit. Amongst our patients 16.4%
experienced problems with their catheter compared to
25.0% in the NCEPOD group. However, complications
were poorly defined in the NCEPOD study and compari-
son between the two studies is hence difficult. Of note is
the fact that PN continues to be prescribed inappropiately
in a percentage of children which may lead to serious or
even life-threatening complications. All effort should
hence be made to avoid the use of PN if clinically not
clearly indicated.
Inappropriate prescribing of PN
In our cohort PN was inappropriately prescribed to chil-
dren with a functional gut when enteral feeds were not
tried vigorously enough and in situations associated with
Table 7 Nutritional complications
Nutritional complication No Percentage among all patients
with PN > 28 days
Vitamins
High vitamin E 15 27,3
High vitamin A 14 25,5
High vitamin D 1 1,8
Low vitamin D 1 1,8
High folate 7 12,7
High vitamin B12 1 1,8
Trace elements
Low Zinc 7 12,7
High Zinc 1 1,8
Low selenium 16 29,1
High selenium 2 3,6
Low copper 9 16,4
High copper 5 9,1
Low iron 4 7,3
High iron 1 1,8
High Manganese 1 1,8
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a temporary feed intolerance. In particular in children
older than 12 months of age, with a good nutritional sta-
tus, post operative PN is considered beneficial only if the
child is expected to remain nil by mouth for more than
7 days and when PN is administered for at least 5 days,
otherwise the risk associated with the administration
outweighs the benefits [9, 24–26].
Main Metabolic complications: hyperphosphatemia,
hypercalcemia, hypermagnesemia, hypophosphatemia
The commonest metabolic complications seen in our
patients were an elevated phosphate, magnesium and
calcium. These minerals have a crucial role in the cellu-
lar physiology of the neuromuscolar and cardiovascular
systems [27]. Derangement can lead to significant path-
ologies including respiratory failure, disruption of the
cardiac conduction system with arrhythmias, complete
heart block, and in severe cases cardiac arrest and coma
[27–35]. In the oncology children rumour lysis syn-
drome may have contributed to these abnormal results
[29]. An overawareness of RS could have also led to
overprescribing of electrolytes. Given that only a small
number of malnourished patients (9.0%) developed
hyperphosphatemia this appears unlikely though. Hypo-
phosphatemia was also commmonly observed in our
population with 23.1% of children/newborns affected.
Hypophosphatemia is associated with respiratory insuffi-
ciency and decreased myocardial contractility, rhabdo-
myolysis, hemolysis, impaired platelet and white blood
cell function, and neurological abnormalities including
seizures [36, 37]. Hypophosphatemia during the first
7-10 days on PN may also be a consequence of RS, a po-
tentially lethal condition which occurs in starved, mal-
nourished or ill metabolically stressed patients when too
much nutrition is provided initially [13, 38]. Based on
this definition we found that up to 21.8% of our patients
were affected but amongst them just 19.7% were mal-
nourished (4,3% of the total population). A study from
2016 on RS in adults receiving artificial support reported
only a 2% incidence. However RS was more rigorously
defined not only by the finding of hypophasphatemia
[39]. Data collected retrospectively on children in the
same year showed that hypophosphatemia, hypokalemia
and hypomagnesimia were frequent in children receiving
inpatient PN before and during the first four days after
starting PN [40] . Malnourished children in this cohort
were found to be more prone to develop low levels of
potassium, wheras patients who received a high intra-
venous protein load had a higher incidence of hypomag-
nesaemia [40].
More than 15 % of newborns who were entered into
the NCEPOD audit experienced low phosphate levels
[9]. However, the authors do not comment whether this
was felt to be a consequence of RS or not. In our cohort
a large proportion of malnourished patients (85.4%) did
not develop hypophosphatemia in the first days after
starting PN. It is standard practice in our hospital to give
extra phosphate at the start of PN in children who are at
high risk of developing RS. The calorie intake is built up
gradually over a few days whilst children are carefully
monitored which may explain the lower incidicence of
hypophosphataemia in our patients.
Hyperglycemia
An excess in serum glucose levels affected 10.6% of our
patients. Hyperglycaemia is associated with a higher in-
fection rate [41], can lead to overfeeding [42, 43] and
even death [44–46]. A glucose intake exceeding the
maximal oxidation rate promotes fat synthesis and de-
position [47, 48] with a large increase in CO2 produc-
tion [49]. Hypercapnia, which was found in 8.9% of our
patients, is compensated by increasing the respiratory
rate or depth of breathing, which is well tolerated by
stable patients but may lead to complications in patients
with respiratory compromise [49]. In addition the over-
feeding of glucose can have a negative impact on liver
function, lead to hepatic steatosis and a rise in serum
transaminases [50, 51]. Neonates receiving PN are par-
ticularly vulnerable to the consequences of hypergly-
cemia which is positively correlated to high morbidity
and mortality, especially in premature and low birth
weight infants [52, 53]. As this age group is prone to de-
veloping low blood sugar levels large amounts of glucose
are often administered to neonates receiving PN which
can easily cause hyperglycemia if children are not moni-
tored closely [52, 53]. Unlike the NCEPOD audit, which
showed a >20% prevalence of hyperglycemia in new-
borns, we only saw elevated glucose levels in 10.45% of
our newborns. Although we were encouraged by these
results there is still a significant amount of work re-
quired to improve blood sugar control in these most vul-
nerable children. The guidelines of the American Society
Table 8 Comparison between our audit and NCEPOD
Current Audit NCEPOD
Newborns Infants/children Newborns Infants/children
No, Percentage No, Percentage No, Percentage No, Percentage
Metabolic complications 50, 74.6 181, 76.7 63, 30.4% 10, 14.3
CVC related complications 11, 16.4 58, 24.6 56, 25.0 /
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for Parenteral and Enteral Nutrition suggest that new-
borns should receive intravenous lipids when dextrose is
infused, as glycerol is the predominant gluconeogenic
substrate [54, 55] and to consider insulin in cases of pro-
longed hyperglycemia [56].
Hepatobiliary complications
In pediatric patients receiving PN, various definitions of
PN-associated cholestasis (PNAC) and intestinal failure–
associated liver disease (IFALD) are used in the literature
[57]. There is hence a great variation in the prevalence
of hepatic complications reported ranging from 7.4% to
84% in children [58–60]. In infants the prevalence of
PNAC appears higher with 30%–70% being affected [58,
61, 62]. In keeping with the definition of the Hepatology
working group of the Bristish Society of Paediatric
Gastroenterology, Hepatology and Nutrition we consid-
ered IFALD as the elevation of LFTs including AST,
ALT, GGT, ALP ×1.5 above the reference range for age
and a bilirubin level > 50 micromoli/L for [61]. The
BPSGHAN position paper consideres persistently ele-
vated LFTs for a minimum of 6 weeks abnormal [61.
However a ESPGHAN position paper from 2015 defines
early IFALD as the presence of hyperbilirubinemia (>20
mmol/L) for at least 2 to 4 weeks [63]. The authors state
further, that children with IF but without IFALD fre-
quently have an isolated increase in transaminases or a
moderate increase in GGT (usually <150 IU/L) [63].
Therefore, we decided to considered a time period of 14
days pathological.
We found deranged LFTs in 106 patients, 35.0% of our
population. Amongst those, 45/106 (42,5%, 14.8% of the
total population) experienced an elevation of more than
one test. We found the occurence of abnormal LFTs was
correlating to the duration of PN and the longer PN was
given the higher the incidence. Our results are in keep-
ing with other reports from the literature. As 21 patients
had a concomitant line infection which is a well docu-
mented cause of liver inflammation our numbers may
have, however been falsely elevated [64].
Early signs of steatosis after two weeks of PN are a
mild to moderate elevation of AST and ALT, whilst
serum alkaline phosphatase and bilirubin are usually not
raised [58]. Cholestasis on the other hand is associated
with elevated serum concentrations of ALP, GGT and
bilirubin [58]. The majority of our patients (82/303;
27.1%) had an isolated rise in ALT suggestive of an in-
flammatory response of the liver or early steatosis. Cho-
lestasis was less common. Steatosis is potentially
reversible even if PN is continued, whilst cholestasis
may progress to cirrhosis and liver failure if weaning off
PN is not possible [58]. However, a significant number
of our patients demonstrated a rise in GGT and bilirubin
affecting 38 (12,5%) and 31 (10,5%) respectively.
Steatosis can be a consequence of intravenous overnutri-
tion [47, 48]. Unfortunately we did not have data avail-
able on the amount of non nitrogen calories provided
per Kcal of body weight and we can hence not comment
if too much nutrients could be held responsible.
CVC related complications
Central venous catheters are integral to pediatric PN ad-
ministration and their benefits should be carefully bal-
anced against the risk they pose [65–68]. CVC related
complication were less common in our population
(16.4%) compared to the NCEPOD audit (25 %) .On the
other hand, central line infections were much more
common in our cohort of infants (4/67) in comparison
to the relatively low numbers (5/264) in the NCEPOD
audit. There is clear need in our very young patients to
reduce infection rates.
CLABSIs are a known complication of PN administra-
tion [69, 70]; a prolonged catheter dwell time is associated
with an increased risk for infection and the microorgan-
isms usually involved are Gram positiva bacteria [71, 72].
CLABSIs account for significant morbidity, mortality and
financial burden to the health care system [72].
In our study 31children (10.2%) developed a central
line infection. The mean duration of PN administration
was longer in these children than in the group which did
not develop any CVC related infection (37 days vs 17
days). Gram positive microorganism were responsible
for altmost 71% of infections, followed by gram negative
bacteria (12.9% ) and candida species (9.7 %). Our re-
sults are simlar to those found in the literature [69–72].
Central venous catheter blockage affected 11.6% of
children. Similar numbers are reported in patients on
PN within 1 to 2 years after catheter placement (14% to
36%) [73]. Catheter occlusion can negatively impact on
patient care: it can lead to a delay or cancellation of
medical procedures, potentially interrupt the administra-
tion of intravenous medication and nutrition and has a
risk of CLABSIs which in turn may lead to catheter re-
moval [74, 75]. We were surprised about the relatively
high incidence of early catheter blockage. However,
many of the patients requiring chemotherapy for malig-
nancies and those post bone marrow trabsplantation re-
quire multiple blood products and their catheter is
accessed frequently for a large number of drugs, which
may account for the number of catheter related prob-
lems encountered.
Nutritional complications: high vitamin A and E and low
selenium levels
In children who received PN longer than 28 days, nutri-
tional complications occured in 35/55 patients. As 18/55
did not have bloods for micronutrients sent the figure
may even be higher. The adequate provision of vitamins
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and trace elements intravenously can be challenging and
we were hence not surprised by the large number of pa-
tients affected. The exact optimal amount of individual
vitamins and trace elements children and neonates re-
quire remains a matter of debate, and only scanty evi-
dence is available from the literature in the last 20 years
[76]. In particular, little is know about the micronutrient
requirements in children with acute and chronic disease.
theri needs may be significantly different to those of
healthy children [6].
The ESPGHAN guidelines state that the actual
amount of vitamins delivered to the patient through PN
may be much lower than the intended dose as vitamins
degradate over time in the PN bag [6]. We were hence
suprised to see the number of children who had high
levels of vitamin A and E. In our PN compounding unit
fat soluble vitamins are added to the lipid emulsion at
the following concentration: retinol 230 IU per Kg, max-
imum dose 2300 IU, which is in keeping with the ESP-
GHAN guidelines of 2005; alfa-tocoferol 0.7 IU per Kg,
maximum 70 IU, which is well below the recommended
dose (2.8-3.5 IU/kg). Both vitamins tend to leach into
the giving set which may lead to further losses [77]. We
therefore expected a deficiency of these vitamins, par-
ticularly vitamin E. However, we found high levels of
vitamin E and A in 27.3% and 25.5% of children rece-
spectivley who received inpatient PN for more than one
month. Both hypervitaminosis and hypovitaminosis A
have been reported in patients who are fully PN depend-
ant [78–80]; Hack et al found elevated vitamin A levels
in approximately one fourth of their patients [81]. Al-
though their results are comparable to ours, their pa-
tients received much higher doses than ours (214% of
the recommended dose). Hypovitaminosis E is more fre-
quently reported in children receiving PN [82]. In con-
trast, we found a large prevalence of high vitamin E
levels in our group of children. We were concerned our
results were falsely elevated tue to the way they were
analysed in our lab. However, the method used (liquid
chromatography) excludes falsely elevated vitamin E
levels and our results hence appear to be genuine. No
child in our study or in the study by Hack et el demon-
strated any symptoms associated with vitamin A or E
toxicity [81]. Multicenter studies or a national database
such as the paediatric electronic British Articificial Nu-
trition Survey (eBANS) may be useful in identifying if
children receiving PN are genuinely at risk of high fat
soluble vitamin levels or whether there is a subgroup of
patients who is more vulnerable.
When anlysing our trace element results we found low
levels of selenium in altmost 30% of children who received
PN for more than 28 days. Selenium deficiency can lead
to significant complications including cardiomyopathy,
arthritis, skeletal myopathy, loss of pigmentation of hair
and skin and macrocytosis [83]. Increased transaminases
and creatinine kinase have been noted in patients on
long-term parenteral nutrition without selenium supple-
mentation [83]. In children with less than 15 kg body
weight, PN bags compounded by our PN pharmacy pro-
vide 25 nanomol/kg/day and in those with more than 15
Kg 4 nanomol/kg/day. Both are in keeping with current
ESPGHAN guidelines. However, the precise requirements
for trace elements in parenteral provision remain still a
matter of debate and alterations in the blood levels of
children on PN as in our group may hence be not
suprising [76]. The results should be interpreted with
caution though, as plasma selenium levels reflect diet-
ary intake rather than selenium stores or bioavailability
[84]. Selenium-dependent enzyme activity in tissue and
body fluids in addition to serum selenium levels may
hence be a better measure [6, 85].
Our results suggest thats methods aiming to detect
micronutrient stores and bioavailability should be devel-
oped to detect a truly deficient state or potentially toxic
levels prior to manifestations of clinical symptoms.
Conclusions
Despite the advancements made since PN was first pre-
scribed to children in the late 1960s, PN is still pre-
scribed inappropriately and complications occur
frequently in the hospital setting. There is clearly still
work to be done to improve inpatient prescribing of PN
to children. The indications for PN have evolved over
the last forty years. Initially PN was prescribed to pa-
tients with a primary pathology of the GI tract [86].
However, in recent years PN is now commonly used for
nutritional support in other conditions [16]. This is
strongly supported by our data, as the majority of chil-
dren received PN for a other conditions than a primary
GI pathology (61.7% non GI vs 38.3% GI). It is still not
clear how the critically ill child should be fed and both
optimal route of feeding (enteral versus parenteral) and
timing for the start of nutritional support is subject to
debate [87]. Given that more and more children are ad-
mitted to paediatric intensive care units urgent random-
ized controlled trials are needed to guide physicians in
the decision making process. Moreover consultation of a
NST has been shown to reduce the number of children
receiving short term PN unnecessarily. When a NST is
consulted enteral feeds are more frequently started early
and the incidence of catheter related and metabolic
complications reduced. Utilisation of an NST therefore
reduces the burden of care and is cost effective [88, 89].
Our hospital is staffed with a NST, and children receiv-
ing PN are reviewed once a week. However, it is cur-
rently not routine practice to consult this team prior to
the start of PN, which may lead to overprescribing of
PN. Studies on adults have shown that mandatory
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involvement of the NST prior to the start of PN reduced
the number of inappropriate PN prescriptions [89]. We
will therefore propose to our hospital executive board
that the same policy should be put in place in our unit
in the future. Moreover, given the high percentage of
children developing complications, it might also be of
benefit to review these most vulnerable of patients more
frequently. Future staffing numbers should take this into
consideration.
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